The Italian Assessment System for Innovative Medicines: An 8-Year Retrospective Analysis of Outcomes, Criteria, Timelines and Funding Dynamics [0.03%]
创新药物的意大利评估体系：为期八年的回顾性分析——结果、标准、时间线和资金动态
Lorenzo Martellone,Camilla Servidio,Marcello Vaccaro et al.
Lorenzo Martellone et al.
Background: The Italian assessment system for innovative medicines represents a distinctive European regulatory approach. Integrated with the Italian Medicines Agency (AIFA), since 2017 it has provided a formal evaluation...
Policy Levers for First-Contact Healthcare Provider Choice: A Discrete Choice Experiment in Shanghai's Hierarchical Medical System [0.03%]
上海分级诊疗背景下基层首诊政策杠杆的离散选择实验研究
Yi Gong
Yi Gong
Background: China's hierarchical medical system seeks to route first-contact care for mild, nonurgent conditions to primary healthcare (PHC), yet hospital-centrism persists. Evidence is needed on how financing and visible...
Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa [0.03%]
南非布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病的经济评价
Rochelle Woudberg,Edina Sinanovic
Rochelle Woudberg
Background: Targeted therapy with Bruton's tyrosine kinase inhibitors has demonstrated promising efficacy and safety outcomes in both untreated and relapsed or refractory chronic lymphocytic leukaemia (CLL); however, evid...
Preferences of Women for Maternal Health Services in Sidama Region, Ethiopia: Discrete Choice Experiment [0.03%]
埃塞俄比亚西达摩地区妇女的妇产健康服务偏好：离散选择实验分析
Daniel Gashaneh Belay,Gizachew A Tessema,Jennifer Dunne et al.
Daniel Gashaneh Belay et al.
Background: Skilled maternal health services, including antenatal care (ANC) services, childbirth services and postnatal care (PNC) services, can save the lives of women and newborns. However, women in resource-limited co...
Towards a Multi-sectoral Approach to Population Health: A Scoping Review of Cross-sectoral Evaluations of Health Interventions [0.03%]
迈向整体性方法改善人口健康：卫生干预措施跨部门评估的系统评价式回顾研究
Rositsa Koleva-Kolarova,Emily Hulse,Bertalan Németh et al.
Rositsa Koleva-Kolarova et al.
Background: Health interventions, particularly those targeted at health promotion and disease prevention, often have a range of impacts that span beyond the healthcare sector. Making the case for investment in these inter...
It's Time to Rethink 'Real-World Evidence': A Call for Terminological Clarity in Health Technology Assessment [0.03%]
是时候重新思考“真实世界证据”：卫生技术评估中术语清晰性的呼吁
Hesam Ghiasvand,Haipeng Liu
Hesam Ghiasvand
Ensuring Epidemiological Consistency in Risk-Stratified Cancer Screening Models: A Novel Approach Based on Flemish Breast Cancer Screening [0.03%]
基于佛兰德乳腺癌筛查的分层癌症筛查模型中确保流行病学一致性的新方法
Max Lelie,Bo VandenBulcke,Nick Verhaeghe et al.
Max Lelie et al.
Objective: We present a novel dynamic risk-stratified breast cancer screening Markov model designed to maintain robust and epidemiologically consistent cancer prevalences, regardless of the number or composition of risk-s...
Indirect Effects in Health Economic Models of Vaccines: Should We Include Them, and How Do We Model Them? [0.03%]
疫苗健康经济模型中的间接效应：我们该如何进行考量和建模？
Rachel J Oidtman,Min Huang,Walter A Orenstein et al.
Rachel J Oidtman et al.
Indirect effects refer to the population-level effects of vaccination on vaccinated and unvaccinated individuals, including herd protection, serotype replacement, and age shifts, which can substantially impact the real-world effectiveness o...
Partnerships in Public Health Economics: Reflective Lessons from UK Obesity Research [0.03%]
英国肥胖症研究中的卫生经济学合作及反思
Humera Sultan,Nafsika Afentou,Luiz F Andrade et al.
Humera Sultan et al.
Background and objective: Partnerships between health economists and multi-sectoral stakeholders are essential for public health economics research. While most evidence comes from low- and middle-income countries, high-in...
Estimation of 'spectrum value': A discrete choice experiment to investigate the willingness-to-pay for narrow-spectrum based on other antimicrobial characteristics [0.03%]
基于其他抗菌特性下的窄谱抗生素的支付意愿调查——一种离散选择实验及光谱值估算
Nadine T Hillock,Gang Chen,Tracy L Merlin et al.
Nadine T Hillock et al.
Background: Narrow-spectrum antimicrobials are likely to drive fewer antimicrobial resistances. However, they may be more expensive than broad-spectrum alternatives. ...